XXII 22nd Century Group Inc.

First Cigarette Authorized by FDA to “Help You Smoke Less” Now Available Across Colorado

First Cigarette Authorized by FDA to “Help You Smoke Less” Now Available Across Colorado

from 22nd Century Group contain 95% less nicotine than conventional cigarettes, greatly reducing nicotine consumption to help smokers smoke less; support State and FDA goals of reducing tobacco harm

DENVER, Oct. 06, 2022 (GLOBE NEWSWIRE) -- There’s a revolutionary new option available for the more than 680,000 adult smokers in Colorado — many of whom are trying to cut back or quit. VLN® brand cigarettes are the first and only combustible tobacco cigarettes to receive a Modified Risk Tobacco Product designation by the FDA and contain minimal to non-addictive levels of nicotine. VLN® cigarettes are now available at all Smoker Friendly locations in the state via a partnership with Creager Mercantile and will be available in Colorado Circle K stores by next week. VLN® is also rolling out to retail locations throughout the state, through a partnership with Eagle Rock Distributing Company, a wholesale partner of Anheuser-Busch.

The VLN® King and VLN® Menthol King cigarettes are substantially lower in nicotine content — 95 percent less — than any other cigarettes currently available to smokers in the United States. These uniquely low levels of nicotine were developed using proprietary modern tobacco breeding techniques from 22nd Century Group, Inc. (Nasdaq: ), a leading agriculture biotechnology company focused on tobacco harm reduction and plant technology/science.

More than 50 government-funded, independent clinical trials under grants from federal organizations including the FDA and National Institutes of Health (NIH) conducted at Johns Hopkins University, Mayo Clinic and other leading U.S. institutions over the past 12 years have that adult smokers who switch to greatly-reduced nicotine content cigarettes:

  • Reduce their cigarettes per day (CDP) by 50 percent after 20 weeks
  • Have more smoke-free days and quit attempts as a group
  • Experience a reduction in cravings and withdrawal symptoms

In June 2022, the Biden-Harris Administration for the FDA’s plans to establish a maximum nicotine level to reduce the addictiveness of cigarettes and other combustible tobacco products. While no cigarette is safe and VLN® must still include the Surgeon General’s warning language on its packaging and marketing materials, 22nd Century is at the forefront of aligning with the FDA’s goal of promoting public health and reducing nicotine use.

“According to the CDC, almost half of the Colorado adult smoking population tried to quit in 2019; our VLN® King and VLN® Menthol King cigarettes are proven to help adults smoke less,” said John Miller, president of 22nd Century Group's Tobacco Business. “Reducing cigarette consumption is important, though challenging, and we are hopeful many smokers will transition away from smoking cigarettes entirely.”

Colorado is the first state where VLN® cigarettes will be fully rolled out, following an exceptionally successful pilot in the Chicago area earlier this year. Despite continually ranking as one of the in the country, more than highly addictive cigarettes. 22nd Century Group chose Colorado for the first statewide rollout due to Colorado’s rapid progress in permitting and facilitating the sale of VLN® products, as evidenced by being one of the first states in the country to produce an MRTP stamp for VLN® and the second Master Settlement Agreement state to approve listing VLN® for sale in their state.

VLN® King and VLN® Menthol King reduced nicotine content cigarettes can be purchased at all Smoker Friendly locations throughout the state and will be available at all Colorado Circle K stores by next week. The cigarettes will also soon be available at almost any location alcoholic beverages are sold, through the Eagle Rock Distributing Company partnership. VLN® will be competitively priced in-line with other major brands at $9 to $9.25 a pack, depending on tax.

Learn more about VLN®’s revolutionary approach to reducing tobacco harm at and click on the ‘Store Locator’ to find the nearest location selling VLN® King and VLN® Menthol King.

About VLN®

VLN® is the first and only FDA MRTP authorized combustible cigarette. Utilizing 22nd Century Group’s proprietary tobacco plant lines, VLN® cigarettes smoke, smell and taste just like a conventional cigarette but contain 95% less nicotine. Numerous independent scientific studies, funded largely by the U.S. Food and Drug Administration, the National Institutes of Health, and other U.S. federal government agencies, have demonstrated that using reduced nicotine content tobacco cigarettes like VLN® helps smokers reduce their nicotine exposure and dependence, smoke fewer cigarettes per day, increase their number of smoke-free days, and double their quit attempts – all with minimal or no nicotine withdrawal symptoms or compensatory smoking behavior. VLN® helps you smoke less. Learn more at . 

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA modified risk tobacco product (MRTP) authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. Learn more at , on , on , and on .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Media Contact:

Paul Raab

Linhart Public Relations

303-951-2551



EN
06/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strength...

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets BUFFALO, NY, Jan. 24, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the acquisition of privately held RX ...

 PRESS RELEASE

22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master Fi...

22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry BUFFALO, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced filing of a U.S. ...

 PRESS RELEASE

22nd Century Group’s GVB Biopharma Opens New Central Distribution Faci...

22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands New distribution facility supports rapidly growing demand for hemp/cannabis products BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- , a 22nd Century Group company (Nasdaq: ), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon...

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022. “We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Inve...

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences: On Tuesday, November 15, 2022, the Company will host one-on-one meetings at the Roth 2nd Annual AgTech Answers Event.On Thursday, November 17, 2022, the Company will ho...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch